Some features of the coronavirus infection course in bronchial asthma patients

Abstract

The outbreak of a new coronavirus infection was officially recognized by the World Health Organization as a global pandemic since March 11, 2020. The pandemic is currently gradually receding, the number of patients is also steadily decreasing. However, these circumstances are not grounds to believe that the virus has been definitively and irrevocably defeated. For this reason, the world medical community is still concerned about the coronavirus’ impact on the course and outcome of various chronic bronchopulmonary diseases. Bronchial asthma has been recognized as one of the leading forms of human somatic pathology throughout the history of mankind and medicine. It is quite natural that the focus of the researchers' attention turned out to be questions about the SARS-CoV-2 virus’ impact on patients suffering from bronchial asthma, starting with the peculiarities of the course of combined pathology and ending with the peculiarities of therapy and subsequent rehabilitation. The issues of coronavirus infection and bronchial asthma pathogenesis were considered. The research data on some features of the development and course of a new coronavirus infection in patients with this profile were analyzed and summarized. The low coronavirus infection prevalence among patients with an allergic bronchial asthma form compared with other phenotypes is shown among such features, data on the effect of eosinophilia on the course of infection are presented, and the basic therapy’s positive effect using inhaled glucocorticosteroids and/or monoclonal antibodies (biological therapy) in severe asthma, is shown in the form of a protective effect that provides a lighter coronavirus infection course. The main features of patient management suffering from bronchial asthma in the conditions of a pandemic are the organization of stable medical control in online telemedicine once monthly, regular examinations in accordance with the severity of the course of the disease and the correction of basic therapy to achieve complete control over the course of asthma.

Keywords

bronchial asthma / coronavirus infection / factor of risk / angiotensin converting enzyme / inhaled glucocorticosteroids / biological therapy / inhaled glucocorticosteroids / monoclonal antibodies

References

[1] Ochani RK, Asad A, Yasmin F, et al COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infections in Medicine. 2021;29(1):20–36.

[2] Ochani R.K., Asad A., Yasmin F., et al COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management // Infections in Medicine. 2021. Vol. 29, No. 1. P. 20–36.

[3] Fisun AYa, Aganov DS, Bazilevich SN. COVID-19 i zabolevaniya vnutrennikh organov: osobennosti vedeniya patsientov. Vremennye klinicheskie rekomendatsii. 2020. P. 131–144. (In Russ.).

[4] Фисун А.Я., Аганов Д.С., Базилевич С.Н. COVID-19 и заболевания внутренних органов: особенности ведения пациентов // Временные клинические рекомендации. 2020. С. 131–144.

[5] Salukhov VV, Kovalevskaya EA. Vitamin D is a strategic blow to coronavirus infection. Medical Council. 2020;(21):218–228. (In Russ.). DOI: 10.21518/2079-701X-2020-21-218-228

[6] Салухов В.В., Ковалевская Е.А. Витамин D – стратегический удар по коронавирусной инфекции // Медицинский совет. 2020. № 21. С. 218–228. DOI: 10.21518/2079-701X-2020-21-218-228

[7] Broadhurst R, Peterson R, Wisnivesky JP, et al. Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? Ann Am Thorac Soc. 2020;17(12):1645–1648. DOI: 10.1513/AnnalsATS.202006-613RL

[8] Broadhurst R., Peterson R., Wisnivesky J.P., et al. Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? // Ann Am Thorac Soc. 2020. Vol. 17, No. 12. P. 1645–1648. DOI: 10.1513/AnnalsATS.202006-613RL

[9] Sunjaya AP, Allida SM, Di Tanna GL, Jenkins CR. Asthma and Coronavirus Disease 2019 Risk: a systematic review and meta-analysis. Eur Respir J. 2021;14(2):210. DOI: 10.1183/13993003.01209-2021

[10] Sunjaya A.P., Allida S.M., Di Tanna G.L., Jenkins C.R. Asthma and Coronavirus Disease 2019 Risk: a systematic review and meta-analysis // Eur Respir J. 2021. Vol. 14, No. 2. P. 210. DOI: 10.1183/13993003.01209-2021

[11] Caminati M, Vultaggio A, Matucci A, et al. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;176(7):106261. DOI: 10.1016/j.rmed.2020.106261

[12] Caminati M., Vultaggio A., Matucci A., et al. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity // Respir Med. 2021. Vol. 176, No. 7. ID 106261. DOI: 10.1016/j.rmed.2020.106261

[13] Avdeev SN, Nenasheva NM, Zhudenkov KV, et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya. 2018;28(3):341–358. (In Russ.). DOI: 10.18093/0869-0189-2018-28-3-341-358

[14] Авдеев С.Н., Ненашева Н.М., Жуденко К.В., и др. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации // Пульмонология. 2018. Т. 28, № 3. С. 341–358. DOI: 10.18093/0869-0189-2018-28-3-341-358

[15] Salukhov VV, Kharitonov MA, Kryukov EV, et al. Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. Medical Council. 2020;(21):96–102. (In Russ.). DOI: 10.21518/2079-701X-2020-21-96-102

[16] Салухов В.В., Харитонов М.А., Крюков Е.В., и др. Актуальные вопросы диагностики, обследования и лечения больных с COVID-19-ассоциированной пневмонией в различных странах и континентах // Медицинский совет. 2020. № 21. С. 96–102. DOI: 10.21518/2079-701X-2020-21-96-102

[17] Rudakov JV, Mitin JA. The immunology special features of bronchial asthma in the patients, with the debut of disease at the age are older than 60 years. Bulletin of the Russian Military Medical Academy. 2009;(1):94–96. (In Russ.).

[18] Рудаков Ю.В., Митин Ю.А. Иммунологические особенности бронхиальной астмы у больных, с дебютом заболевания в возрасте старше 60 лет // Вестник Российской военно-медицинской академии. 2009. № 1. С. 94–96.

[19] Trushina EYu, Kostina EM, Orlova EA. Patients with bronchial asthma who have undergone COVID-19. Farmateka. 2021;(5):76–80. (In Russ.). DOI: 10.18565/pharmateca.2021.5.76-80

[20] Трушина Е.Ю., Костина Е.М., Орлова Е.А. Больные бронхиальной астмой, перенесшие COVID-19 // Фарматека. 2021. № 5. С. 76–80. DOI: 10.18565/pharmateca.2021.5.76-80

[21] Fedoseev GB, Trofimov VI. Bronkhial'naya astma. Saint Petersburg: Normedizdat, 2006. 308 p. (In Russ.).

[22] Федосеев Г.Б., Трофимов В.И. Бронхиальная астма. Санкт-Петербург: Нормедиздат, 2006. 308 с.

[23] Kharitonov MA, Salukhov VV, Kryukov EV, et al. Viral pneumonia: a new look at an old problem (review). Medical Council. 2021;(16): 60–77. (In Russ.). DOI: 10.21518/2079-701X-2021-16-60-77

[24] Харитонов М.А., Салухов В.В., Крюков Е.В., и др. Вирусные пневмонии: новый взгляд на старую проблему (обзор литературы) // Медицинский совет. 2021. № 16. С. 60–77. DOI: 10.21518/2079-701X-2021-16-60-77

[25] Kalinichenko UYu, Shvarts VD. Koronavirusnaya infektsiya COVID-19 I BA. Forcipe. 2021;4(1):833–834. (In Russ.).

[26] Калиниченко У.Ю., Шварц В.Д. Коронавирусная инфекция COVID-19 и БА // Forcipe. 2021. Т. 4, № 1. С. 833–834.

[27] Gaisina AR, Shilovskiy IP, Nikonova AA, et al. The study of balance of Th1/Th2 immune response during virus-induced asthma exacerbation. Russian Journal of Allergy. 2016;13(4–5):20–28. (In Russ.). DOI: 10.36691/RJA347

[28] Гайсина А.Р., Шкловский И.П., Никонова А.А., и др. Изучение баланса Th1/Th2-иммунного ответа при вирус-индуцированных осложнениях бронхиальной астмы // Российский аллергологический журнал. 2016. Т. 13, № 4–5. С. 20–28. DOI: 10.36691/RJA347

[29] Asiryn EG, Matyuschenko OV, Matsuk ON. Pathogenetic aspects of bronchial asthma. Maternal and child health. 2020;(1):102–107. (In Russ.).

[30] Асирян Е.Г., Матющенко О.В., Мацук О.Н. Патогенетические аспекты бронхиальной астмы // Охрана материнства и детства. 2020. № 1. С. 102–107.

[31] Tsai S-C, Lu C-C, Bau D-T, et al. Approaches towards fighting the COVID-19 pandemic (Review). Int J Mol Med. 2021;47(1):3–22. DOI: 10.3892/ijmm.2020.4794

[32] Tsai S.-C., Lu C.-C., Bau D.-T., et al. Approaches towards fighting the COVID-19 pandemic (Review) // Int J Mol Med. 2021. Vol. 47, No. 1. P. 3–22. DOI: 10.3892/ijmm.2020.4794

[33] Osipova VV, Osipova GL, Zaryanova EA, Terekhov DV. Asthma and COVID-19: Аn overview of the guidelines for the management of asthma patients during the COVID-19 pandemic. Pulmonologiya. 2021;31(5): 663–670. (In Russ.). DOI: 10.18093/0869-0189-2021-31-5-663-670

[34] Осипова В.В., Осипова Г.Л., Зарянова Е.А., Терехов В.Д. БА и COVID-19: обзор рекомендаций по ведению пациентов с бронхиальной астмой во время пандемии COVID-19 // Пульмонология. 2021. Т. 31, № 5. С. 663–670. DOI: 10.18093/0869-0189-2021-31-5-663-670

[35] Nenasheva NM. Fenotipy bronkhial'noi astmy i vybor terapii. Prakticheskaya pul'monologiya. 2014;(2):2–11. (In Russ.).

[36] Ненашева Н.М. Фенотипы бронхиальной астмы и выбор терапии // Практическая пульмонология. 2014. № 2. С. 2–11.

[37] Ovsyannikov ES, Аvdeev SN, Budnevskiy AV, et al. Bronchial Asthma and COVID-19: Comorbidity Issues. Tuberculosis and Lung Diseases. 2021;99(9):6–14. (In Russ.). DOI: 10.21292/2075-1230-2021-99-9-6-14

[38] Овсянников Е.С., Авдеев С.Н., Будневский А.В., и др. БА и COVID-19: вопросы коморбидности // Туберкулез и болезни легких. 2021. Т. 99, № 9. С. 6–14. DOI: 10.21292/2075-1230-2021-99-9-6-14

[39] Choi YJ, Park J-Y, Lee HS, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021;57(3):2226. DOI: 10.1183/13993003.02226-2020

[40] Choi Y.J., Park J.-Y., Lee H.S., et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19 // Eur Respir J. 2021. Vol. 57, No. 3. P. 2226. DOI: 10.1183/13993003.02226-2020

[41] Anka AU, Tahir MI, Abubakar SD, et al. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2020;6(2):1298. DOI: 10.1111/sji.12998

[42] Anka A.U., Tahir M.I., Abubakar S.D., et al. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management // Scand J Immunol. 2020. Vol. 6, No. 2. ID 1298. DOI: 10.1111/sji.12998

[43] Val'chuk IN. Sovremennye problemy ostrykh respiratornykh infektsii i bronkhial'noi astmy: sbornik nauchnykh trudov Belorusskogo gosudarstvennogo meditsinskogo universiteta. T. 1. Minsk: GU RNMB, 2011. P. 7. (In Russ.).

[44] Вальчук И.Н. Современные проблемы острых респираторных инфекций и бронхиальной астмы: сборник научных трудов Белорусского государственного медицинского университета. Т. 1. Минск: ГУ РНМБ, 2011. С. 7.

[45] Nicholson K, Kent J, Ireland D. Respiratory viruses and exacerbations of asthma in adults. BMJ . 1993;3079(6910):982–986. DOI: 10.1136/bmj.307.6910.982

[46] Nicholson K., Kent J., Ireland D. Respiratory viruses and exacerbations of asthma in adults // BMJ . 1993. Vol. 307, No. 6910. P. 982–986. DOI: 10.1136/bmj.307.6910.982

[47] Ayoubkhani D, Khunti K, Nafilyan V, Maddox T. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372(49):693. DOI: 10.1136/bmj.n693

[48] Ayoubkhani D., Khunti K., Nafilyan V., Maddox T. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study // BMJ. 2021. Vol. 372, No. 49. P. 693. DOI: 10.1136/bmj.n693

[49] Global Initiative for Asthma. GINA guidance about COVID-19 and asthma 2022. 223 р.

[50] Green I, Merzon E, Vinker S, Golan-Conen A. COVID-19 Susceptibility in Bronchial Asthma. J Allergy Clin Immunol Pract. 2021;9(2):684–692. DOI: 10.1016/j.jaip.2020.11.020

[51] Green I., Merzon E., Vinker S., Golan-Conen A. COVID-19 Susceptibility in Bronchial Asthma // J Allergy Clin Immunol Pract. 2021. Vol. 9, No. 2. P. 684–692. DOI: 10.1016/j.jaip.2020.11.020

[52] Izquierdo JL, Almonacid C, Gonzalez Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021;57(3):2142. DOI: 10.1183/13993003.03142-2020

[53] Izquierdo J.L., Almonacid C., Gonzalez Y., et al. The impact of COVID-19 on patients with asthma // Eur Respir J. 2021. Vol. 57, No. 3. P. 2142. DOI: 10.1183/13993003.03142-2020

[54] Rosenberg HF, Foster PS. Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies. Semin Immunopathol. 2021;43(3):383–392. DOI: 10.1007/s00281-021-00850-3

[55] Rosenberg H.F., Foster P.S. Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies // Semin Immunopathol. 2021. Vol. 43, No. 3. P. 383–392. DOI: 10.1007/s00281-021-00850-3

[56] Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75(11):2829–2845. DOI: 10.1111/all.14429

[57] Radzikowska U., Ding M., Tan G., et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors // Allergy. 2020. Vol. 75, No. 11. P. 2829–2845. DOI: 10.1111/all.14429

[58] Skevaki C, Karsonova A, Karaulov A, et al. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol. 2020;146(6):1295–1301. DOI: 10.1016/j.jaci.2020.09.017

[59] Skevaki C., Karsonova A., Karaulov A., et al. Asthma-associated risk for COVID-19 development // J Allergy Clin Immunol. 2020. Vol. 146, No. 6. P. 1295–1301. DOI: 10.1016/j.jaci.2020.09.017

[60] Wark PAB, Pathinayake PS, Eapen MS, Sohal SS. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights. Eur Respir J. 2021;58(2):2100920. DOI: 10.1183/13993003.00920-2021

[61] Wark P.A.B., Pathinayake P.S., Eapen M.S., Sohal S.S. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights // Eur Respir J. 2021. Vol. 58, No. 2. ID 2100920. DOI: 10.1183/13993003.00920-2021

[62] Gagne M, Cheung JLS, Kouri A, et al. A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm. Respir Med. 2021:106568. DOI: 10.1016/j.rmed.2021.106568

[63] Gagne M., Cheung J.L.S., Kouri A., et al. A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm // Respir Med. 2021. ID 106568. DOI: 10.1016/j.rmed.2021.106568

[64] Davido B, Partouche B, Jaffal K, et al. Eosinopenia in COVID-19: What we missed so far? J Microbiol Immunol Infect. 2021;54(5): 1006–1007. DOI: 10.1016/j.jmii.2021.01.013

[65] Davido B., Partouche B., Jaffal K., et al. Eosinopenia in COVID-19: What we missed so far? // J Microbiol Immunol Infect. 2021. Vol. 54, No. 5. P. 1006–1007. DOI: 10.1016/j.jmii.2021.01.013

[66] Lieberman-Cribbin W, Rapp J, Alpert N, et al. The Impact of Asthma on Mortality in Patients With COVID-19. Chest. 2020;158(6):2290–2291. DOI: 10.1016/j.chest.2020.05.575

[67] Lieberman-Cribbin W., Rapp J., Alpert N., et al. The Impact of Asthma on Mortality in Patients With COVID-19 // Chest. 2020. Vol. 158, No. 6. P. 2290–2291. DOI: 10.1016/j.chest.2020.05.575

[68] Gasmi A, Peana M, Pivina L, et al. Interrelations between COVID-19 and other disorders. Clin Immunol. 2021;224(28):108. DOI: 10.1016/j.clim.2020.108651

[69] Gasmi A., Peana M., Pivina L., et al. Interrelations between COVID-19 and other disorders // Clin Immunol. 2021. Vol. 224, No. 28. P. 108. DOI: 10.1016/j.clim.2020.108651

[70] Peredel'skaya MYu, Nenasheva NM. BA i COVID-19: chto izvestno o sochetanii dvukh diagnozov u odnogo bol'nogo. Astma i allergiya. 2021;(2):3–8. (In Russ.).

[71] Передельская М.Ю., Ненашева Н.М. БА и COVID-19: что известно о сочетании двух диагнозов у одного больного // Астма и аллергия. 2021. № 2. С. 3–8.

[72] Zhang J-J, Dong X, Cao Y-Y. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7): 1730–1741. DOI: 10.1111/all.14238

[73] Zhang J.-J., Dong X., Cao Y.-Y. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China // Allergy. 2020. Vol. 75, No. 7. P. 1730–1741. DOI: 10.1111/all.14238

[74] Zhao L, Zhang Y-P, Yang X, Liu X. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019. Allergy. 2021;76(2):562–564. DOI: 10.1111/all.14455

[75] Zhao L., Zhang Y.-P., Yang X., Liu X. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019 // Allergy. 2021. Vol. 76, No. 2. P. 562–564. DOI: 10.1111/all.14455

[76] Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155–168. DOI: 10.1016/j.resinv.2019.12.005

[77] Yamaya M., Nishimura H., Deng X., et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells // Respir Investig. 2020. Vol. 58, No. 3. P. 155–168. DOI: 10.1016/j.resinv.2019.12.005

[78] Agusti A, Torres F, Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respir Med. 2021;9(7):682–683. DOI: 10.1016/S2213-2600(21)00171-5

[79] Agusti A., Torres F., Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 // Lancet Respir Med. 2021. Vol. 9, No. 7. P. 682–683. DOI: 10.1016/S2213-2600(21)00171-5

[80] Khludova LG. BA i COVID-19. Astma i allergiya. 2020;(1):3–5. (In Russ.).

[81] Хлудова Л.Г. БА и COVID-19 // Астма и аллергия. 2020. № 1. С. 3–5.

[82] Hojo M, Terada-Hirashima J, Sugiyama H. COVID-19 and bronchial asthma: current perspectives. Global Health and Medicine. 2021;3(2):67–72. DOI: 10.35772/ghm.2020.01117

[83] Hojo M., Terada-Hirashima J., Sugiyama H. COVID-19 and bronchial asthma: current perspectives // Global Health and Medicine. 2021. Vol. 3, No. 2. P. 67–72. DOI: 10.35772/ghm.2020.01117

[84] Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543–1545. DOI: 10.1111/all.14348

[85] Johnston S.L. Asthma and COVID-19: is asthma a risk factor for severe outcomes? // Allergy. 2020. Vol. 75, No. 7. P. 1543–1545. DOI: 10.1111/all.14348

[86] Riegel B, Westland H, Iovino P, et al. Characteristics of self-care interventions for patients with a chronic condition: A scoping review. Int J Nurs Stud. 2021;116(2):103713. DOI: 10.1016/j.ijnurstu.2020.103713

[87] Riegel B., Westland H., Iovino P., et al. Characteristics of self-care interventions for patients with a chronic condition: A scoping review // Int J Nurs Stud. 2021. Vol. 116, No. 2. P. 103713. DOI: 10.1016/j.ijnurstu.2020.103713

[88] Eger K, Bel EH. Asthma and COVID-19: do we finally have answers? Eur Respir J. 2021;57(3):2004451. DOI: 10.1183/13993003.04451-2020

[89] Eger K., Bel E.H. Asthma and COVID-19: do we finally have answers? // Eur Respir J. 2021. Vol. 57, No. 3. ID 2004451. DOI: 10.1183/13993003.04451-2020

[90] Heffler E, Detoraki A, Contoli M, et al. COVID-19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments. Allergy. 2020;15(4):111–123. DOI: 10.22541/au.159335800.09668428

[91] Heffler E., Detoraki A., Contoli M., et al. COVID-19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments // Allergy. 2020. Vol. 15, No. 4. P. 111–123. DOI: 10.22541/au.159335800.09668428

[92] Denneny EK, Garthwaite HS, Heightman MJ, Porter JC. A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up? Ann Am Thorac Soci. 2021;18(6):1082–1083. DOI: 10.1513/AnnalsATS.202101-048LE

[93] Denneny E.K., Garthwaite H.S., Heightman M.J., Porter J.C. A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up? // Ann Am Thorac Soci. 2021. Vol. 18, No. 6. P. 1082–1083. DOI: 10.1513/AnnalsATS.202101-048LE

[94] Tabatabaian F, Ledford DK. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy. 2018;11(5):53–61. DOI: 10.2147/JAA.S107982

[95] Tabatabaian F., Ledford D.K. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history // J Asthma Allergy. 2018. Vol. 11, No. 5. P. 53–61. DOI: 10.2147/JAA.S107982

[96] Petrov DV, Belevskii AS. Vedenie patsientov s bronkhial'noi astmoi v usloviyakh pandemii COVID-19. Astma i allergiya. 2020;(1):6–11. (In Russ.).

[97] Петров Д.В., Белевский А.С. Ведение пациентов с бронхиальной астмой в условиях пандемии COVID-19 // Астма и аллергия. 2020. № 1. С. 6–11.

[98] Fomina DS, Serdotetskova SA, Ivanova MS, et al. Management of patients with COVID-19 and asthma: literature review and clinical experience of the authors. Prakticheskaya pul'monologiya. 2020;(2):3–15. (In Russ.).

[99] Фомина Д.С., Сердотецкова С.А., Иванова М.С., и др. Ведение пациентов с COVID-19 и бронхиальной астмой: обзор литературы и клинический опыт авторов // Практическая пульмонология. 2020. № 2. С. 3–15.

[100] Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772. DOI: 10.1016/S2213-2600(21)00160-0

[101] Ramakrishnan S., Nicolau D.V., Langford B., et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial // Lancet Respir Med. 2021. Vol. 9, No. 7. P. 763–772. DOI: 10.1016/S2213-2600(21)00160-0

RIGHTS & PERMISSIONS

Kharitonov M.A., Burkova Y.S., Salukhov V.V., Sapronova A.S.